1 minute read
MEDICAL ONCOLOGY
Abbrev. Title
Protocol Title
849-010 KRYSTAL-10 Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation
849-012 KRYSTAL-12 A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
CELC-G-301 VIKTORIA-1 A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
D9670C00001 DESTINYBreast06 A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease H as Progressed on Endocrine Therapy in the Metastatic Setting
DS1602-A-U301 TROPION-LUNG01
Phase 3 Randomized Study of DS-1062A versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
HERTHENA–Lung02 A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus PlatinumBased Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-Mutated (EGFRm) Non-Small Cell Lung Cancer (NSCLC) After Failure of EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
R1979-ONC-1625 ELM-2 An Open-Label Study to Assess the Anti-Tumour Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-cell NonHodgkin Lymphoma
XL092-303 STELLAR-303 A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer